585 related articles for article (PubMed ID: 18480196)
1. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
[TBL] [Abstract][Full Text] [Related]
2. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
[TBL] [Abstract][Full Text] [Related]
3. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
4. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
[TBL] [Abstract][Full Text] [Related]
5. The risk associated with aprotinin in cardiac surgery.
Mangano DT; Tudor IC; Dietzel C; ;
N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
[TBL] [Abstract][Full Text] [Related]
6. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
[TBL] [Abstract][Full Text] [Related]
7. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
[TBL] [Abstract][Full Text] [Related]
8. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study.
Baric D; Biocina B; Unic D; Sutlic Z; Rudez I; Vrca VB; Brkic K; Ivkovic M
Eur J Cardiothorac Surg; 2007 Mar; 31(3):366-71; discussion 371. PubMed ID: 17218108
[TBL] [Abstract][Full Text] [Related]
9. Aprotinin use in cardiac surgery patients at low risk for requiring blood transfusion.
Kristeller JL; Stahl RF; Roslund BP; Roke-Thomas M
Pharmacotherapy; 2007 Jul; 27(7):988-94. PubMed ID: 17594204
[TBL] [Abstract][Full Text] [Related]
10. The effect of aprotinin on outcome after coronary-artery bypass grafting.
Shaw AD; Stafford-Smith M; White WD; Phillips-Bute B; Swaminathan M; Milano C; Welsby IJ; Aronson S; Mathew JP; Peterson ED; Newman MF
N Engl J Med; 2008 Feb; 358(8):784-93. PubMed ID: 18287601
[TBL] [Abstract][Full Text] [Related]
11. [Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery].
Yasim A; Aşik R; Atahan E
Anadolu Kardiyol Derg; 2005 Mar; 5(1):36-40. PubMed ID: 15755701
[TBL] [Abstract][Full Text] [Related]
12. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
Breuer T; Martin K; Wilhelm M; Wiesner G; Schreiber C; Hess J; Lange R; Tassani P
Eur J Cardiothorac Surg; 2009 Jan; 35(1):167-71; author reply 171. PubMed ID: 19027313
[TBL] [Abstract][Full Text] [Related]
13. Aprotinin during coronary-artery bypass grafting and risk of death.
Schneeweiss S; Seeger JD; Landon J; Walker AM
N Engl J Med; 2008 Feb; 358(8):771-83. PubMed ID: 18287600
[TBL] [Abstract][Full Text] [Related]
14. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O
Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162
[TBL] [Abstract][Full Text] [Related]
15. Coronary artery bypass grafting after aprotinin: are we doing better?
Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Levi M; Cromheecke ME; de Jonge E; Prins MH; de Mol BJ; Briët E; Büller HR
Lancet; 1999 Dec; 354(9194):1940-7. PubMed ID: 10622296
[TBL] [Abstract][Full Text] [Related]
17. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Henry D; Carless P; Fergusson D; Laupacis A
CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).
Vanek T; Jares M; Fajt R; Straka Z; Jirasek K; Kolesar M; Brucek P; Maly M
Eur J Cardiothorac Surg; 2005 Oct; 28(4):563-8. PubMed ID: 16125959
[TBL] [Abstract][Full Text] [Related]
19. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures.
Ipema HJ; Tanzi MG
Ann Pharmacother; 2012 Jan; 46(1):97-107. PubMed ID: 22202494
[TBL] [Abstract][Full Text] [Related]
20. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.
Takagi H; Manabe H; Kawai N; Goto SN; Umemoto T
Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):98-101. PubMed ID: 19380335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
